Johnson & Johnson

09/27/2024 | Press release | Distributed by Public on 09/27/2024 11:06

DARZALEX® (daratumumab) based maintenance regimens show clinically meaningful deep and durable responses in transplant eligible patients with newly diagnosed multiple myeloma